AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06278701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: late-evening snacks
Description: have an additional meal 1h before bedtime (total calories 200-275kcal, protein 11.5g-18g, complex carbohydrates 25-55g).
Study NCT05456997 — intervention group
Intervention type: PROCEDURE
Intervention: Muscle biopsy
Description: Patients will have muscle biopsies taken at time of surgery under general anaesthetic. Open biopsies from the operation field (abdominal wall) will be taken by the surgical team without extending or making new skin incisions. Briefly, muscle samples (approximately 0.5cm3) are excised and haemostasis secured. The muscle biopsies will be snap frozen and stored at -80°C for the analysis of pathways relevant to muscle homeostasis using biochemical and molecular techniques.
Study NCT05817955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) with Ruxolitinib
Description: 1. Antibiotics: Antibiotic treatment is positively given when symptoms related to infection, and other support treatment is strengthened.~2. Blood products: Infuse the blood products according to the patient's blood routine test. Drugs that need to be used by other diseases must be recorded in detail in the case report form, including the general name of the drug, the dosage of the medication, and the frequency of administration. Drugs are not allowed to be combined: Avoiding the use of granulocyte colony-stimulating factor (G-CSF), there may be risk of spleen rupture.
Study NCT05144893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Mindfullness-Based Intervention
Description: Virtual administration of the social support components of an adapted 4-week Mindfulness Based Cognitive Therapy for Postpartum Depression (MBCT-PD) intervention. Each session includes a review of assigned online mindfulness practice and barriers to practice, other homework if also assigned, psychoeducation, and mindfulness practices relevant to the session's theme.
Study NCT06110364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Tragus Stimulation
Description: Low-Level Tragus Stimulation via TENS unit will be monitored with a Holter.
Study NCT06110364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability- Biofeedback
Description: Heart Rate Variability- Biofeedback will be monitored with a Holter.
Study NCT06110364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Therapy
Description: Conventional Medical Therapy by Beta Blockers will be added to subjects usual care by their doctor if they are not already taking this medication.
Study NCT05783128 — intervention group
Intervention type: OTHER
Intervention: Airway management techniques (exposure)
Description: The exposure reffers to the different methods of airway management during general or regional anesthesia.
Study NCT05598541 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical or non-surgical treatment
Description: Surgical treatment (depending on diagnosis) Non-surgical treatment (such as exercise therapy, pain medication, watch and wait)
Study NCT05509920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S-PRG barrier coat
Description: S-PRG filler was the best composition of compressive strength and F- and B release acid buffering capacity. It was found to be the most promising for use as a novel cement.
Study NCT05509920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: S-PRG barrier coat
Description: S-PRG filler was the best composition of compressive strength and F- and B release acid buffering capacity. It was found to be the most promising for use as a novel cement.
Study NCT05239884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product A with 1.5% nicotine
Description: P1211216, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study NCT06435988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in the pecha kucha technique
Description: Providing labor training to pregnant women with the Pecha Kucha technique
Study NCT04910529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Hatha yoga, which is one of the most basic yoga methods, will be applied to the students in the study. During each practice within the scope of Hatha yoga, students; breathing exercises, relaxation techniques and warm-up exercises will be applied respectively. In addition to these, asanas (yoga postures) with balance, stretching, relaxation and strengthening components will be applied to the students.
Study NCT04648488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental early mobilisation
Description: early activ assisted exercises treatment
Study NCT04648488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aktive comparator standrad treatmnet
Description: standard treatment with a plaster 3 weeks and then active assisted exercises
Study NCT05561816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxymethylquinoxalindioxyde
Description: Dioxidin®, 0.025% solution for local and external use (Valenta Farm, Russia).
Study NCT05561816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium
Description: Miramistin®, topical solution 0.01% (Infamed K LLC, Russia)
Study NCT04262882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multilevel Family Planning Intervention
Description: The intervention is comprised of community dialogues, or facilitated discussions, aimed to reshape community norms around gender roles, equity, and family size, and critically analyze the social and community influences of family-wealth and poverty with the overall goal of reconstructing individual attitudes and group norms on paths to/definitions of a successful family inclusive of family planning. Dialogues are enhanced to address knowledge, motivation, self-efficacy, and relationship dynamics, tailored to men and women. Sessions include both gender segregated and integrated groups with couples in the community.
Study NCT04262882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time and attention matched control
Description: This intervention serves as the attention-matched control. The format and delivery will mirror that of the Family Health = Family Wealth intervention (i.e., number, timing, and duration of sessions). The focus of the intervention is on community sanitation and at-home hygiene (hand-washing, food preparation) following an intervention manual that was developed for community groups in Uganda.
Study NCT05964348 — intervention group
Intervention type: PROCEDURE
Intervention: CT-Scan
Description: semi-automated analyse by anatomical landmarks with a dedicated fully automated software
Study NCT06107751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ramped position group
Description: This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
Study NCT06107751 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sniffing position group
Description: This position will be achieved by placing a 7 cm pillow under the occiput.
Study NCT05507125 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mental health
Description: Early life exposure to abuse and development of hidradenitis suppurativa
Study NCT06413563 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood count
Description: Complete blood count will be done for all patients and then will search about CD4, CD8 T lymphocyte cells surface markers~* CD56 Natural killer cells surface marker~* CD19 Lymphocyte cells surface marker
Study NCT05239884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product B with 1.5% nicotine
Description: P1213516, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study NCT05363722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310（0.5mg/kg）
Description: IBI310 0.5mg/kg IV d1 Q6W
Study NCT05363722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310（0.3mg/kg）
Description: IBI310 0.3mg/kg IV d1 Q6W
Study NCT05363722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: sintilimab 200 mg IV d1 Q3W
Study NCT05363722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab 15 mg/kg IV d1，Q3W
Study NCT04974840 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training combined with/ without thera-band
Description: Treadmill walking training with thera-band Treadmill walking training without thera-band
Study NCT04974840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill training combined with/ without thera-band
Description: Treadmill walking training with thera-band Treadmill walking training without thera-band
Study NCT04700761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia
Description: Anesthesia induction: thiopental, rocuronium, desflurane + single dose of alfentanil for endotracheal intubation Anesthesia maintenance: desflurane (without any opioid) Rescue for hypertension, tachycardia: desflurane and beta blocker/calcium channel blocker
Study NCT04700761 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-using anesthesia
Description: Anesthesia induction: thiopental, rocuronium, desflurane + continuous infusion of remifentanil (TCI, Minto model) Anesthesia maintenance: desflurane, remifentanil Rescue for hypertension, tachycardia: desflurane, remifantanil and beta blocker/calcium channel blocker
Study NCT05744778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: In addition to the physical therapy and exercise program, the dry needling group will consist of patients who have had 3 sessions of dry needling applied to the trigger points in the trapezius muscle, 5 days apart.
Study NCT05744778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy and rehabilitation
Description: The physical therapy and rehabilitation group will consist of patients who will be applied the same exercise program together with the same physical therapy applications (superficial heat (infrared lamp), transcutaneous electrical nerve stimulation (TENS) and therapeutic ultrasound (TUS)) 5 sessions per week for 3 weeks.
Study NCT04848467 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA Vaccine (CVnCoV)
Description: Two intramuscular injections administered 28 days apart at a dose level of 12 μg mRNA.
Study NCT04848467 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV)
Description: One intramuscular injection as 0.5 mL. Each 0.5 mL dose will contain 15 μg haemagglutinin (HA) from each of the four influenza strains.
Study NCT04848467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One intramuscular injection as normal saline \[0.9% NaCl\].
Study NCT05523752 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Proseal Laryngeal Mask
Description: insertion of Proseal Laryngeal Mask
Study NCT05523752 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Classic Laryngeal Mask
Description: insertion of Classic Laryngeal Mask
Study NCT05523752 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: I-gel
Description: insertion of I-gel
Study NCT05523752 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Suprema Laryngeal Mask
Description: insertion of Suprema Laryngeal Mask
Study NCT05239884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product C with 1.5% nicotine
Description: P1213416, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study NCT05366816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 37.5 mg of Sunitinib orally (PO), once daily on a 28-day treatment cycle.
Study NCT05366816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: 120.0 mg of Regorafenib, once daily by mouth 3 weeks on 1 week off on a 4-week treatment cycle.
Study NCT04786821 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Exercise Training
Description: Participants will receive interventions by an exercise specialist for up to 30 minutes based on the participant's tolerance. The exercises used in control group will depend on the individual and their abilities as evaluated in the baseline assessment session. Possible exercises include arm crank, recumbent cycle, and chair exercises. These sessions will be delivered by a member of the research team.
Study NCT04786821 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phoenix Exoskeleton suit
Description: Participants will aim to walk wearing the Exoskeleton for up to 30 minutes. Based on the participant's tolerance, the duration of walking can be shorter and can be split into shorter intervals to achieve more activity. Over the sessions, based on the participants' tolerance, gradually the duration of walking can be increased with shorter breaks. This will be delivered by a research physiotherapist.
Study NCT06422221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Receiving 600 mg oral Clindamycin 1 hour before general anesthesia and before any dental manipulation
Study NCT06422221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Receiving 100 mg oral Doxycycline 1 hour before general anesthesia and before any dental manipulation
Study NCT05859152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zona Pellucida-Bound Sperm Selection for ICSI
Description: one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that was bound to the ZP of an immature oocyte.
Study NCT05859152 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine Embryologist Selected Sperm
Description: one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that has been selected based on morphology and mobility characteristics by the embryologist per routine.
Study NCT05232279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testofen 300mg
Description: Testofen in capsule form - To be taken as a 300mg dosage (2 capsules) once daily for 12 weeks.
Study NCT05232279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testofen 600mg
Description: Testofen in capsule form - To be taken as a 600mg dosage (2 capsules) once daily for 12 weeks.
Study NCT05232279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: The placebo will consist of maltodextrin and will appear identical to the Testofen capsules. The placebo will be administered as per the active treatment - 2 capsules once daily for 12 weeks.
Study NCT06014203 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Edema measurement
Description: Subcutaneous fluid measurements will be made 3 times in total, before the surgery, immediately after the surgery and 24 hours after the surgery. Measurements will be made with the MoistureMeterD Compact local edema measuring device.~Points to be measured:~1. Midpoint of the upper trapezius muscle~2. 5 cm distal to anterior acromion~3. 5cm distal to lateral acromion~4. 5cm distal to posterior acromion~5. 3cm medial to the axilla~6. Anterior cubital fossa~7. Carpal tunnel
Study NCT05424796 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Physiological saline
Description: Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, hemostasis was achieved by checking the saline soaked cotton pellet.
Study NCT05424796 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hemostasis and cavity disinfection with NaOCl
Description: Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, 2.5% NaOCl soaked cotton pellets were placed over canal orifices.
Study NCT05014789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control-IQ technology 2.0
Description: All subjects wearing the t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor
Study NCT05625295 — intervention group
Intervention type: OTHER
Intervention: data collection protocol in clinical history
Description: collection of data from the clinical history according to the established protocol
Study NCT06228482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
Description: Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
Study NCT05829005 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)
Description: TMS is a form of 'non-invasive brain stimulation', i.e. it is a way of stimulating the brain from outside the head. It works by holding a magnetic coil approximately the size of a small side plate against the head (it rests on the scalp) which then delivers magnetic pulses that stimulate the underlying brain. It was developed over 30 years ago and has been increasingly used to treat a number of neurological and psychiatric disorders. It is considered a relatively safe and generally well-tolerated treatment.
Study NCT05829005 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)
Description: TMS is a form of 'non-invasive brain stimulation', i.e. it is a way of stimulating the brain from outside the head. It works by holding a magnetic coil approximately the size of a small side plate against the head (it rests on the scalp) which then delivers magnetic pulses that stimulate the underlying brain. It was developed over 30 years ago and has been increasingly used to treat a number of neurological and psychiatric disorders. It is considered a relatively safe and generally well-tolerated treatment.
Study NCT06200168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz.
Study NCT06491940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Patients will receives Losartan (LS) 50 mg per day.
Study NCT06491940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan + Hydrochlorothiazide
Description: Patients will be given Losartan LS (50 mg per day) and Hydrochlorothiazide (HCTZ) 12.5 mg per day as a combination therapy.
Study NCT06200168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard antiemetic treatment
Description: Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.
Study NCT06200168 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham electroacupuncture
Description: The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid de qi sensation.
Study NCT04447300 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high power application
Description: Radiofrequency delivery was performed in a point-by point fashion and continuously (an inter-lesion distance of 6 mm) with 50 W and 70 W and the ablation time for each point is limited to 7s and repeated if needed till the Unipolar signal modification turn to complete positive R wave.
Study NCT06200168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard antiemetic treatment
Description: Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.All the antiemetic drugs used are the same as those in the true acupuncture group.
Study NCT04892524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual multidisciplinary review
Description: The virtual multidisciplinary review involves participants being reviewed by a multi-disciplinary team of specialist doctors, nurses and radiologists in a virtual environment. The team will analyse radiologic scans and make a recommendations for any follow-up scans, procedures or appointments that may be required
Study NCT05143905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7503
Description: Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).